Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

The EC approval also now means that Libtayo can be used to treat certain patients across four types of cancer within the European Union: advanced squamous cell carcinoma (SCC), advanced basal cell ...

which currently comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung ...

Libtayo (cemiplimab), to treat advanced non-small cell lung cancer (NSCLC) and locally advanced basal cell carcinoma (BCC). The agreement was signed in a letter of intent on March 3 to set the ...

Combination therapies, such as Regeneron’s Libtayo (cemiplimab) and Merck’s Keytruda (pembrolizumab), are creating new treatment possibilities for advanced skin cancers, including basal cell carcinoma ...

Other types of cancer that aren't carcinomas invade the body in different ways. Those cancers begin in other types of tissue, such as: Basal cell carcinoma. This is the most common form of all ...

These enzymes, called creatine kinases (CK), allow cells to transport energy produced at the mitochondria to where it is needed throughout the cell. Cancer cells rely on this machinery for ...